BioLineRx (BLRX) Operating Leases (2018 - 2025)

BioLineRx's Operating Leases history runs 8 years deep, the most recent figure standing at $1.2 million for Q4 2025.

• On a quarterly basis, Operating Leases fell 24.45% year-over-year to $1.2 million in Q4 2025; TTM through Dec 2025 was $1.2 million, a 24.45% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, down 24.45% from the prior year.
• Operating Leases slipped to $1.2 million in Q4 2025 per BLRX's latest filing, from $1.6 million in the prior quarter.
• Across five years, Operating Leases topped out at $1.8 million in Q4 2023 and bottomed at $1.2 million in Q4 2025.
• The 5-year median for Operating Leases is $1.7 million (2021), against an average of $1.6 million.
• Across the five-year window, Operating Leases climbed 5.15% in 2023 and slipped 24.45% in 2025, its largest moves.
• Year by year, Operating Leases stood at $1.7 million in 2021, then grew by 0.17% to $1.7 million in 2022, then gained by 5.15% to $1.8 million in 2023, then dropped by 11.83% to $1.6 million in 2024, then declined by 24.45% to $1.2 million in 2025.
• Per Business Quant, the three latest BLRX Operating Leases figures stand at $1.2 million (Q4 2025), $1.6 million (Q4 2024), and $1.8 million (Q4 2023).